Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

Awaiting Public Project Summary

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

1928 heralded the discovery by CE Keeler of photoreceptors in the eye that were not rods or cones but which controlled our body clocks; but it’s only recently it has become truly researched and more thoroughly understood. Leading researchers are discovering other ways daylight (circadian light) affects health and well-being of our bodies from birth to old age. Many are now researching ways to treat conditions such as heart disease, obesity, cancer and our main focus - Dementia. Our focus is on delivery of light and how best to administer it to those who need prescription like doses to keep body clocks in rhythm. It is our aim to personalise light so that each person’s prescription can be changed as they age and as their eyes receive light in a diminished way due to ageing of the eye. For Dementia patients, as their symptoms develop their sleep/wake cycle can shift out of phase. Lack of sleep negatively affects anyone of any age so for those already suffering dementia it can be disorientating and frightening. Drugs are often used to keep patients calm and to help them sleep, at a cost of up to £300 per person per month. However this can throw patients even further out of sync with natural rhythms and exasperate symptoms in a vicious cycle. Our aim is develop a wearable device used by people in early Dementia stages to improve quality of life by enhancing natural circadian body rhythms; potentially enabling people to spend longer at home before professional care is required. By elongating time spent before care home support is required can save upwards of £500 per week per patient plus the cost of drugs required. This market assessment study seeks to identify an optimal market entry point for our circadian lighting device by consulting stakeholders and key influencers in dementia care industry (care homes, carers, and dementia charities, social and medical care opinion leaders) directly to assess their willingness to adopt a new approach.

Utilising artificial circadian light to meet the needs and requirements of the general population via personal devices or general illumination. This will potentially have the benefit of of enhancing health, well-being and increasing energy levels. Other impacts will be improved sleep patterns, possible reduction in obesity. improved mental health, jet lag relief, improved ability to learn and potentially reduce the chances of early onset Alzhiemers.